Medirom Healthcare Technologies Inc. — Form 6-K Summary
Business Context and Reporting Period
This Form 6-K covers December 2022 and reports a Nasdaq continued-listing deficiency concerning the Company’s American Depositary Shares (ADSs). The Company is a foreign private issuer that files annual reports on Form 20-F.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, market capitalization amounts, or other operating metrics. It states only that the Company failed to satisfy Nasdaq’s $35 million minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2).
Material Changes and Listing Status
- On December 28, 2022, Nasdaq notified the Company that its ADSs would be suspended from trading and delisted at the opening of business on January 6, 2023, unless the Company requested a hearing.
- The Company stated that it intended to timely request a hearing before a Nasdaq Hearings Panel by the January 4, 2023, 4:00 p.m. Eastern Time deadline.
- A timely hearing request would stay further suspension or delisting action at least through the hearing process and expiration of any extension period granted by the Panel.
- The Company previously received a June 2022 Nasdaq deficiency notice and was granted a 180-calendar-day period, through December 27, 2022, to regain compliance. It did not regain compliance by that date.
- The Company issued a related press release on December 30, 2022, furnished as Exhibit 99.1.
Outlook, Risks, and Unusual Items
The principal unusual item is the pending Nasdaq suspension and delisting determination. The Nasdaq Panel may grant an extension, but the filing provides no assurance that the Company will retain its listing or satisfy any continued-listing conditions.
Key risks include an unsuccessful appeal, failure to meet Nasdaq’s continued-listing requirements, denial of relief or an extension, and failure to evidence compliance within any extended period. The Company’s forward-looking statements are subject to the risks described in its 2021 Form 20-F and other SEC filings.
Investor Verification Points
- Verify whether the Company submitted the Nasdaq hearing request by January 4, 2023.
- Verify the Panel’s decision, any extension granted, and the ultimate status of the ADS listing.
- Review subsequent SEC filings for any change in Nasdaq compliance, trading venue, or delisting status.
- Assess the Company’s financial condition and market capitalization using subsequent financial statements, as this Form 6-K does not provide those figures.